The Experts below are selected from a list of 267 Experts worldwide ranked by ideXlab platform
J Hierholzer - One of the best experts on this subject based on the ideXlab platform.
-
Bioceramic vertebral augmentation with a calcium sulphate/hydroxyapatite composite (Cerament™ SpineSupport) in vertebral compression fractures due to osteoporosis
European Spine Journal, 2010Co-Authors: Michael Rauschmann, Akhil Verheyden, Robert Pflugmacher, Thomas Werba, Sven Schmidt, Thomas Vogl, J HierholzerAbstract:A prospective, non-randomized multicenter study was initiated to study efficacy and safety of a partly resorbable composite of calcium sulphate and hydroxyapatite (Cerament™ SpineSupport), a novel, injectable bioceramic, in osteoporotic patients with vertebral compression fractures during 18-month follow-up. Fifteen patients with low-energy trauma and 1–2 vertebral compression fractures verified by magnetic resonance imaging were recruited to undergo percutaneous bioceramic vertebral augmentation under fluoroscopy. The patients were treated with a highly flowable bioceramic containing calcium sulphate, hydroxyapatite and the non-ionic Radiocontrast Agent iohexol, with final setting time within 1 h. After the procedure, the patients were allowed to mobilize after 2 h. Pain (VAS), occurrence of remote and adjacent fractures, and Quality of Life (QoL; SF-36 and EQ-5D) was recorded during 18 months. The injected volume of the composite material ranged from 2.8 to 9 mL (mean 4.2 mL). Pre-operative VAS score was mean 70.3 (CI95% ±8.7) with an immediate post-operative pain relief, which was maintained at the 4-week visit (mean 26.4 with CI95% ±16.1) and 8-week visit (mean 18.0 with CI95% ±13.5 pain relief). Eighty percent of the patients demonstrated a clinical improvement. The pain relief was maintained over 18 months and no adjacent fractures were observed. There was a statistically significant improvement of physical components in the QoL assessment. No extra-vertebral leakage or neurological deficits were reported in this series. This first prospective multicenter study on a partly resorbable bioceramic material indicate that fracture healing can be achieved with sustained pain relief over a follow-up period of 18 months in an osteoporotic patient population with vertebral compression fractures.
-
bioceramic vertebral augmentation with a calcium sulphate hydroxyapatite composite cerament spinesupport in vertebral compression fractures due to osteoporosis
European Spine Journal, 2010Co-Authors: Michael Rauschmann, Thomas J Vogl, Akhil Verheyden, Robert Pflugmacher, Thomas Werba, Sven Schmidt, J HierholzerAbstract:A prospective, non-randomized multicenter study was initiated to study efficacy and safety of a partly resorbable composite of calcium sulphate and hydroxyapatite (Cerament™ SpineSupport), a novel, injectable bioceramic, in osteoporotic patients with vertebral compression fractures during 18-month follow-up. Fifteen patients with low-energy trauma and 1–2 vertebral compression fractures verified by magnetic resonance imaging were recruited to undergo percutaneous bioceramic vertebral augmentation under fluoroscopy. The patients were treated with a highly flowable bioceramic containing calcium sulphate, hydroxyapatite and the non-ionic Radiocontrast Agent iohexol, with final setting time within 1 h. After the procedure, the patients were allowed to mobilize after 2 h. Pain (VAS), occurrence of remote and adjacent fractures, and Quality of Life (QoL; SF-36 and EQ-5D) was recorded during 18 months. The injected volume of the composite material ranged from 2.8 to 9 mL (mean 4.2 mL). Pre-operative VAS score was mean 70.3 (CI95% ±8.7) with an immediate post-operative pain relief, which was maintained at the 4-week visit (mean 26.4 with CI95% ±16.1) and 8-week visit (mean 18.0 with CI95% ±13.5 pain relief). Eighty percent of the patients demonstrated a clinical improvement. The pain relief was maintained over 18 months and no adjacent fractures were observed. There was a statistically significant improvement of physical components in the QoL assessment. No extra-vertebral leakage or neurological deficits were reported in this series. This first prospective multicenter study on a partly resorbable bioceramic material indicate that fracture healing can be achieved with sustained pain relief over a follow-up period of 18 months in an osteoporotic patient population with vertebral compression fractures.
Mehmet Ali Oturan - One of the best experts on this subject based on the ideXlab platform.
-
Elimination of Radiocontrast Agent diatrizoic acid by photo-Fenton process and enhanced treatment by coupling with electro-Fenton process
Environmental Science and Pollution Research, 2016Co-Authors: Elvira Bocos, Marta Pazos, Nihal Oturan, M. Ángeles Sanromán, Mehmet Ali OturanAbstract:The removal of Radiocontrast Agent diatrizoic acid (DIA) from water was performed using photo-Fenton (PF) process. First, the effect of H_2O_2 dosage on mineralization efficiency was determined using ultraviolet (UV) irradiation. The system reached a maximum mineralization degree of 60 % total organic carbon (TOC) removal at 4 h with 20 mM initial H_2O_2 concentration while further concentration values led to a decrease in TOC abatement efficiency. Then, the effect of different concentrations of Fenton’s reAgents was studied for homogeneous Fenton process. Obtained results revealed that 0.25 mM Fe^3+ and 20 mM H_2O_2 were the best conditions, achieving 80 % TOC removal efficiency at 4 h treatment. Furthermore, heterogeneous PF treatment was developed using iron-activated carbon as catalyst. It was demonstrated that this catalyst is a promising option, reaching 67 % of TOC removal within 4 h treatment without formation of iron leachate in the medium. In addition, two strategies of enhancement for process efficiency are proposed: coupling of PF with electro-Fenton (EF) process in two ways: photoelectro-Fenton (PEF) or PF followed by EF (PF-EF) treatments, achieving in both cases the complete mineralization of DIA solution within only 2 h. Finally, the Microtox tests revealed the formation of more toxic compounds than the initial DIA during PF process, while, it was possible to reach total mineralization by both proposed alternatives (PEF or PF-EF) and thus to remove the toxicity of DIA solution.
-
Elimination of Radiocontrast Agent Diatrizoic acid from water by electrochemical advanced oxidation: Kinetics study, mechanism and mineralization pathway
Journal of Electroanalytical Chemistry, 2016Co-Authors: Elvira Bocos, Nihal Oturan, M. Ángeles Sanromán, Mehmet Ali OturanAbstract:Abstract Diatrizoic acid (DIA) is an iodinated X-ray contrast media commonly used in hospitals. It is persistent and recalcitrant in aquatic environments and difficult to biodegrade. Thus, we studied its removal from aquatic medium by two electrochemical advanced oxidation processes: anodic oxidation and electro-Fenton using BDD anode and carbon felt cathode. The effect of two of the most important variables on, i.e., applied current intensity (both processes) and catalyst concentration (electro-Fenton) was assessed to optimize oxidative degradation of DIA and mineralization rate of its aqueous solution. 1000 mA current intensity and 0.2 mM catalyst (Fe2 +) concentration (at pH 3) were determined as optimal operating values for its effective removal from water based on the following parameters: concentration decay of DIA, total organic carbon removal rate and mineralization current efficiency. The rate constant for oxidation of DIA by OH was determined using competition kinetics method and found be 3.96 × 108 L mol− 1 s− 1. Obtained results showed a quick and complete mineralization of DIA solution. In addition, the identification of aromatic intermediates, short-chain carboxylic acids and mineral ions released to the solution during electro-Fenton treatment allowed us proposing a plausible mineralization mechanism of DIA by OH generated in the process. Finally, the toxicity of treated solutions along time was assessed following the luminescence inhibition of the marine bacteria Vibrio fischeri, using Microtox® method.
David S Miller - One of the best experts on this subject based on the ideXlab platform.
-
endothelin b receptor mediated regulation of atp driven drug secretion in renal proximal tubule
Molecular Pharmacology, 2000Co-Authors: Rosalinde Masereeuw, Sylvie A Terlouw, R A M H Van Aubel, Frans G M Russel, David S MillerAbstract:In the kidney, endothelins (ETs) are important regulators of blood flow, glomerular hemodynamics, and sodium and water homeostasis. They have been implicated in the pathophysiology of acute ischemic renal failure, nephrotoxicity by cyclosporine, cisplatin and Radiocontrast Agents, and vascular rejection of kidney transplants. Here, we used intact killifish renal proximal tubules, fluorescent substrates for Mrp2 (fluorescein-methotrexate, FL-MTX) and P-glycoprotein (a fluorescent CSA derivative, NBD-CSA), and confocal microscopy to reveal a new role for renal ET: regulation of ATP-driven drug transport in proximal tubule. Subnanomolar to nanomolar concentrations of ET-1 rapidly reduced the cell-to-tubular lumen transport of both fluorescent compounds. These effects were prevented by an ETB receptor antagonist but not by an ETA receptor antagonist. Immunostaining with an antibody to mammalian ETB receptors showed specific localization to the basolateral membrane of the fish tubular epithelial cells. ET-1 effects on transport were blocked by protein kinase C-selective inhibitors, implicating protein kinase C in ET-1 signaling. Finally, the nephrotoxic Radiocontrast Agent iohexol reduced cell-to-lumen FL-MTX and NBD-CSA transport, and these effects were abolished by an ETB receptor antagonist. These are the first results linking ET to the control of xenobiotic transport and the first demonstrating control of renal multidrug resistance-associated protein 2 and P-glycoprotein by a hormone.
Michael Rauschmann - One of the best experts on this subject based on the ideXlab platform.
-
Bioceramic vertebral augmentation with a calcium sulphate/hydroxyapatite composite (Cerament™ SpineSupport) in vertebral compression fractures due to osteoporosis
European Spine Journal, 2010Co-Authors: Michael Rauschmann, Akhil Verheyden, Robert Pflugmacher, Thomas Werba, Sven Schmidt, Thomas Vogl, J HierholzerAbstract:A prospective, non-randomized multicenter study was initiated to study efficacy and safety of a partly resorbable composite of calcium sulphate and hydroxyapatite (Cerament™ SpineSupport), a novel, injectable bioceramic, in osteoporotic patients with vertebral compression fractures during 18-month follow-up. Fifteen patients with low-energy trauma and 1–2 vertebral compression fractures verified by magnetic resonance imaging were recruited to undergo percutaneous bioceramic vertebral augmentation under fluoroscopy. The patients were treated with a highly flowable bioceramic containing calcium sulphate, hydroxyapatite and the non-ionic Radiocontrast Agent iohexol, with final setting time within 1 h. After the procedure, the patients were allowed to mobilize after 2 h. Pain (VAS), occurrence of remote and adjacent fractures, and Quality of Life (QoL; SF-36 and EQ-5D) was recorded during 18 months. The injected volume of the composite material ranged from 2.8 to 9 mL (mean 4.2 mL). Pre-operative VAS score was mean 70.3 (CI95% ±8.7) with an immediate post-operative pain relief, which was maintained at the 4-week visit (mean 26.4 with CI95% ±16.1) and 8-week visit (mean 18.0 with CI95% ±13.5 pain relief). Eighty percent of the patients demonstrated a clinical improvement. The pain relief was maintained over 18 months and no adjacent fractures were observed. There was a statistically significant improvement of physical components in the QoL assessment. No extra-vertebral leakage or neurological deficits were reported in this series. This first prospective multicenter study on a partly resorbable bioceramic material indicate that fracture healing can be achieved with sustained pain relief over a follow-up period of 18 months in an osteoporotic patient population with vertebral compression fractures.
-
bioceramic vertebral augmentation with a calcium sulphate hydroxyapatite composite cerament spinesupport in vertebral compression fractures due to osteoporosis
European Spine Journal, 2010Co-Authors: Michael Rauschmann, Thomas J Vogl, Akhil Verheyden, Robert Pflugmacher, Thomas Werba, Sven Schmidt, J HierholzerAbstract:A prospective, non-randomized multicenter study was initiated to study efficacy and safety of a partly resorbable composite of calcium sulphate and hydroxyapatite (Cerament™ SpineSupport), a novel, injectable bioceramic, in osteoporotic patients with vertebral compression fractures during 18-month follow-up. Fifteen patients with low-energy trauma and 1–2 vertebral compression fractures verified by magnetic resonance imaging were recruited to undergo percutaneous bioceramic vertebral augmentation under fluoroscopy. The patients were treated with a highly flowable bioceramic containing calcium sulphate, hydroxyapatite and the non-ionic Radiocontrast Agent iohexol, with final setting time within 1 h. After the procedure, the patients were allowed to mobilize after 2 h. Pain (VAS), occurrence of remote and adjacent fractures, and Quality of Life (QoL; SF-36 and EQ-5D) was recorded during 18 months. The injected volume of the composite material ranged from 2.8 to 9 mL (mean 4.2 mL). Pre-operative VAS score was mean 70.3 (CI95% ±8.7) with an immediate post-operative pain relief, which was maintained at the 4-week visit (mean 26.4 with CI95% ±16.1) and 8-week visit (mean 18.0 with CI95% ±13.5 pain relief). Eighty percent of the patients demonstrated a clinical improvement. The pain relief was maintained over 18 months and no adjacent fractures were observed. There was a statistically significant improvement of physical components in the QoL assessment. No extra-vertebral leakage or neurological deficits were reported in this series. This first prospective multicenter study on a partly resorbable bioceramic material indicate that fracture healing can be achieved with sustained pain relief over a follow-up period of 18 months in an osteoporotic patient population with vertebral compression fractures.
Norimasa Iwasaki - One of the best experts on this subject based on the ideXlab platform.
-
Cytotoxic Effects of the Radiocontrast Agent Iotrolan and Anesthetic Agents Bupivacaine and Lidocaine in Three- Dimensional Cultures of Human Intervertebral Disc Nucleus Pulposus Cells: Identification of the Apoptotic Pathways
2016Co-Authors: Koji Iwasaki, Hideki Sudo, Katsuhisa Yamada, Manabu Ito, Norimasa IwasakiAbstract:Background: Discography and discoblock are imaging procedures used to diagnose discogenic low back pain. Although needle puncture of the intervertebral disc (IVD) itself induces disc degeneration, the Agents used in these procedures may also have harmful effects on IVD cells. The purpose of this study was to analyze whether Radiocontrast Agents and local anesthetic Agents have detrimental effects on human nucleus pulposus (NP) cells. Methods: Healthy human NP cells were cultured for 7 days in three-dimensional (3D) cell–alginate bead composites, and were then exposed to clinically relevant doses of a Radiocontrast Agent (iotrolan) or local anesthetic (lidocaine or bupivacaine). Cell viability and apoptosis were measured by confocal microscopy and flow cytometry. On the basis of caspase expression profiles, the apoptotic pathways activated by the Agents were identified by Western blot analysis. Results: The Radiocontrast Agent iotrolan did not affect NP cell viability or induce apoptosis. In contrast, both the anesthetic Agents significantly decreased cell viability and increased the apoptotic cell number in a time- and dose-dependent manner. After 120 min, 2 % lidocaine and 0.5 % bupivacaine decreased percent live cells to 13 % and 10%, respectively (p,0.05). The number of apoptotic cells was doubled by increasing lidocaine dosage from 1 % to 2 % (23 % and 42%) and bupivacaine from 0.25 % to 0.50 % (25 % and 48%) (p,0.05). Western blot analysis revealed that both anesthetic Agents upregulated cleaved caspase-3 and caspase-8, whereas only bupivacaine upregulated cleaved caspase-9
-
cytotoxic effects of the Radiocontrast Agent iotrolan and anesthetic Agents bupivacaine and lidocaine in three dimensional cultures of human intervertebral disc nucleus pulposus cells identification of the apoptotic pathways
PLOS ONE, 2014Co-Authors: Koji Iwasaki, Hideki Sudo, Katsuhisa Yamada, Norimasa IwasakiAbstract:BACKGROUND: Discography and discoblock are imaging procedures used to diagnose discogenic low back pain. Although needle puncture of the intervertebral disc (IVD) itself induces disc degeneration, the Agents used in these procedures may also have harmful effects on IVD cells. The purpose of this study was to analyze whether Radiocontrast Agents and local anesthetic Agents have detrimental effects on human nucleus pulposus (NP) cells. METHODS: Healthy human NP cells were cultured for 7 days in three-dimensional (3D) cell-alginate bead composites, and were then exposed to clinically relevant doses of a Radiocontrast Agent (iotrolan) or local anesthetic (lidocaine or bupivacaine). Cell viability and apoptosis were measured by confocal microscopy and flow cytometry. On the basis of caspase expression profiles, the apoptotic pathways activated by the Agents were identified by Western blot analysis. RESULTS: The Radiocontrast Agent iotrolan did not affect NP cell viability or induce apoptosis. In contrast, both the anesthetic Agents significantly decreased cell viability and increased the apoptotic cell number in a time- and dose-dependent manner. After 120 min, 2% lidocaine and 0.5% bupivacaine decreased percent live cells to 13% and 10%, respectively (p<0.05). The number of apoptotic cells was doubled by increasing lidocaine dosage from 1% to 2% (23% and 42%) and bupivacaine from 0.25% to 0.50% (25% and 48%) (p<0.05). Western blot analysis revealed that both anesthetic Agents upregulated cleaved caspase-3 and caspase-8, whereas only bupivacaine upregulated cleaved caspase-9. CONCLUSIONS/SIGNIFICANCE: The present study demonstrates that iotrolan does not affect the viability of healthy human NP cells. In contrast, the two anesthetic Agents commonly used in discography or discoblock may cause extensive damage to IVDs by inducing apoptotic cell death.
-
Cytotoxic effects of the Radiocontrast Agent iotrolan and anesthetic Agents bupivacaine and lidocaine in three-dimensional cultures of human intervertebral disc nucleus pulposus cells: identification of the apoptotic pathways.
PLOS ONE, 2014Co-Authors: Koji Iwasaki, Hideki Sudo, Katsuhisa Yamada, Norimasa IwasakiAbstract:BACKGROUND: Discography and discoblock are imaging procedures used to diagnose discogenic low back pain. Although needle puncture of the intervertebral disc (IVD) itself induces disc degeneration, the Agents used in these procedures may also have harmful effects on IVD cells. The purpose of this study was to analyze whether Radiocontrast Agents and local anesthetic Agents have detrimental effects on human nucleus pulposus (NP) cells. METHODS: Healthy human NP cells were cultured for 7 days in three-dimensional (3D) cell-alginate bead composites, and were then exposed to clinically relevant doses of a Radiocontrast Agent (iotrolan) or local anesthetic (lidocaine or bupivacaine). Cell viability and apoptosis were measured by confocal microscopy and flow cytometry. On the basis of caspase expression profiles, the apoptotic pathways activated by the Agents were identified by Western blot analysis. RESULTS: The Radiocontrast Agent iotrolan did not affect NP cell viability or induce apoptosis. In contrast, both the anesthetic Agents significantly decreased cell viability and increased the apoptotic cell number in a time- and dose-dependent manner. After 120 min, 2% lidocaine and 0.5% bupivacaine decreased percent live cells to 13% and 10%, respectively (p
-
cytotoxic effects of the Radiocontrast Agent iotrolan and anesthetic Agents bupivacaine and lidocaine in three dimensional cultures of human intervertebral disc nucleus pulposus cells identification of the apoptotic pathways
PLOS ONE, 2014Co-Authors: Koji Iwasaki, Hideki Sudo, Katsuhisa Yamada, Norimasa IwasakiAbstract:Background Discography and discoblock are imaging procedures used to diagnose discogenic low back pain. Although needle puncture of the intervertebral disc (IVD) itself induces disc degeneration, the Agents used in these procedures may also have harmful effects on IVD cells. The purpose of this study was to analyze whether Radiocontrast Agents and local anesthetic Agents have detrimental effects on human nucleus pulposus (NP) cells.
-
Impact of Radiocontrast Agents and local anesthetic Agents on the viability of human nucleus pulposus (NP) cells.
2014Co-Authors: Koji Iwasaki, Hideki Sudo, Katsuhisa Yamada, Manabu Ito, Norimasa IwasakiAbstract:NP cell–alginate 3D composites were exposed to saline, Radiocontrast Agent (iotrolan) or local anesthetic Agents (lidocaine and bupivacaine) for 30, 60, or 120 min. After an additional 24 h, they were stained with calcein AM (live cells; green) and propidium iodide (PI; dead cells; red). (A) Confocal laser scanning micrographs of the NP cell–alginate 3D composites after the exposures. Scale bar: 100 μm. (B) Time-dependent effects on cell viability. (C) Dose-dependent effects on viability after 60 min. All data are from five independent experiments (mean ± SE; *, p